Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
14:27
A Romanian and a Slovak were reported to the police in Germany for noisy work done on Sunday.
14:26
Donald Trump has sparked a new wave of controversy after he published a photograph in which he portrayed himself as Elvis Presley
14:09
The honorary advisor of the interim prime minister Ilie Bolojan: Romania continues to risk being downgraded to the "junk" category.
13:59
Five people and a company, sent to trial in the Czech Republic for a VAT fraud of 17.4 million euros involving goods from China.
13:59
ECFR calls for a common EU response after the entry of approximately 60,000 migrants in Ceuta
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
International
Alphabet announces the sale of shares up to 80 billion dollars to finance the development of artificial intelligence
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
